PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Motixafortide→

Motixafortide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
664334-36-5
Molecular formula
C97H144FN33O19S2
Molecular weight
2159.6 g/mol
Drug class
C-X-C chemokine receptor 4 (CXCR4) antagonisthaematopoietic stem-cell mobiliser
Mechanism of action
Blocks CXCR4 binding to its ligand CXCL12/SDF-1α, disrupting retention and homing of haematopoietic stem cells in the bone marrow and mobilising CD34-positive stem cells into peripheral blood.
Indications / reported uses
  • In combination with filgrastim (G-CSF) to mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma; not indicated for stem-cell mobilisation in leukaemia

Sources: NLM DailyMed — APHEXDA (motixafortide), updated 28 October 2025 · Manufacturer prescribing information — APHEXDA · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Motixafortide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Motixafortide Permitted Daily Exposure (PDE) report (the Motixafortide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Motixafortide Occupational Exposure Limit (OEL) report (the Motixafortide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.